PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 000A87

Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus

Identifieur interne : 000A87 ( PascalFrancis/Curation ); précédent : 000A86; suivant : 000A88

Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus

Auteurs : Gary P. Kobinger [Canada] ; Isabelle Meunier [Canada] ; Ami Patel [Canada] ; Stéphane Pillet [Canada] ; Jason Gren [Canada] ; Shane Stebner [Canada] ; Anders Leung [Canada] ; James L. Neufeld [Canada] ; Darwyn Kobasa [Canada] ; Veronika Von Messling [Canada]

Source :

The Journal of infectious diseases [ 0022-1899 ] ; 2010.

RBID : Pascal:10-0203512

Descripteurs français

Pascal (Inist)
- Virus grippal A, Efficacité, Vaccin, Infection.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Efficiency, Infection, Influenza A virus, Vaccine.

Abstract

Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.

A01	`01`	`1`		`@0 0022-1899`
A02	`01`			`@0 JIDIAQ`
A03		`1`		`@0 J. infect. dis.`
A05				`@2 201`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus`
A11	`01`	`1`		`@1 KOBINGER (Gary P.)`
A11	`02`	`1`		`@1 MEUNIER (Isabelle)`
A11	`03`	`1`		`@1 PATEL (Ami)`
A11	`04`	`1`		`@1 PILLET (Stéphane)`
A11	`05`	`1`		`@1 GREN (Jason)`
A11	`06`	`1`		`@1 STEBNER (Shane)`
A11	`07`	`1`		`@1 LEUNG (Anders)`
A11	`08`	`1`		`@1 NEUFELD (James L.)`
A11	`09`	`1`		`@1 KOBASA (Darwyn)`
A11	`10`	`1`		`@1 VON MESSLING (Veronika)`
A14	`01`			`@1 Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada @3 CAN @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 9 aut.`
A14	`02`			`@1 Department of Medical Microbiology, University of Manitoba @3 CAN @Z 1 aut. @Z 3 aut. @Z 9 aut.`
A14	`03`			`@1 National Centre for Foreign Animal Disease, Canadian Food Inspection Agency @2 Winnipeg, Manitoba @3 CAN @Z 8 aut.`
A14	`04`			`@1 Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec @2 Laval, Quebec @3 CAN @Z 2 aut. @Z 4 aut. @Z 10 aut.`
A20				`@1 1000-1006`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2052 @5 354000181584600070`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 10-0203512`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Journal of infectious diseases`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002B05`
C02	`03`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Efficacité @5 05`
C03	`02`	`X`	`ENG`	`@0 Efficiency @5 05`
C03	`02`	`X`	`SPA`	`@0 Eficacia @5 05`
C03	`03`	`X`	`FRE`	`@0 Vaccin @5 06`
C03	`03`	`X`	`ENG`	`@0 Vaccine @5 06`
C03	`03`	`X`	`SPA`	`@0 Vacuna @5 06`
C03	`04`	`X`	`FRE`	`@0 Infection @5 07`
C03	`04`	`X`	`ENG`	`@0 Infection @5 07`
C03	`04`	`X`	`SPA`	`@0 Infección @5 07`
C07	`01`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`02`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 137`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001381

Links to Exploration step

Pascal:10-0203512

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</title>
<author><name sortKey="Kobinger, Gary P" sort="Kobinger, Gary P" uniqKey="Kobinger G" first="Gary P." last="Kobinger">Gary P. Kobinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Meunier, Isabelle" sort="Meunier, Isabelle" uniqKey="Meunier I" first="Isabelle" last="Meunier">Isabelle Meunier</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Patel, Ami" sort="Patel, Ami" uniqKey="Patel A" first="Ami" last="Patel">Ami Patel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Pillet, Stephane" sort="Pillet, Stephane" uniqKey="Pillet S" first="Stéphane" last="Pillet">Stéphane Pillet</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Gren, Jason" sort="Gren, Jason" uniqKey="Gren J" first="Jason" last="Gren">Jason Gren</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Stebner, Shane" sort="Stebner, Shane" uniqKey="Stebner S" first="Shane" last="Stebner">Shane Stebner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Leung, Anders" sort="Leung, Anders" uniqKey="Leung A" first="Anders" last="Leung">Anders Leung</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Neufeld, James L" sort="Neufeld, James L" uniqKey="Neufeld J" first="James L." last="Neufeld">James L. Neufeld</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Kobasa, Darwyn" sort="Kobasa, Darwyn" uniqKey="Kobasa D" first="Darwyn" last="Kobasa">Darwyn Kobasa</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Von Messling, Veronika" sort="Von Messling, Veronika" uniqKey="Von Messling V" first="Veronika" last="Von Messling">Veronika Von Messling</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0203512</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0203512 INIST</idno>
<idno type="RBID">Pascal:10-0203512</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001381</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</title>
<author><name sortKey="Kobinger, Gary P" sort="Kobinger, Gary P" uniqKey="Kobinger G" first="Gary P." last="Kobinger">Gary P. Kobinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Meunier, Isabelle" sort="Meunier, Isabelle" uniqKey="Meunier I" first="Isabelle" last="Meunier">Isabelle Meunier</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Patel, Ami" sort="Patel, Ami" uniqKey="Patel A" first="Ami" last="Patel">Ami Patel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Pillet, Stephane" sort="Pillet, Stephane" uniqKey="Pillet S" first="Stéphane" last="Pillet">Stéphane Pillet</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Gren, Jason" sort="Gren, Jason" uniqKey="Gren J" first="Jason" last="Gren">Jason Gren</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Stebner, Shane" sort="Stebner, Shane" uniqKey="Stebner S" first="Shane" last="Stebner">Shane Stebner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Leung, Anders" sort="Leung, Anders" uniqKey="Leung A" first="Anders" last="Leung">Anders Leung</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Neufeld, James L" sort="Neufeld, James L" uniqKey="Neufeld J" first="James L." last="Neufeld">James L. Neufeld</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Kobasa, Darwyn" sort="Kobasa, Darwyn" uniqKey="Kobasa D" first="Darwyn" last="Kobasa">Darwyn Kobasa</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Von Messling, Veronika" sort="Von Messling, Veronika" uniqKey="Von Messling V" first="Veronika" last="Von Messling">Veronika Von Messling</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Efficiency</term>
<term>Infection</term>
<term>Influenza A virus</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Efficacité</term>
<term>Vaccin</term>
<term>Infection</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1899</s0>
</fA01>
<fA02 i1="01"><s0>JIDIAQ</s0>
</fA02>
<fA03 i2="1"><s0>J. infect. dis.</s0>
</fA03>
<fA05><s2>201</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KOBINGER (Gary P.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MEUNIER (Isabelle)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PATEL (Ami)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PILLET (Stéphane)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GREN (Jason)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STEBNER (Shane)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LEUNG (Anders)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>NEUFELD (James L.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KOBASA (Darwyn)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>VON MESSLING (Veronika)</s1>
</fA11>
<fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>1000-1006</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2052</s2>
<s5>354000181584600070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0203512</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Journal of infectious diseases</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Efficacité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Efficiency</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Eficacia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Infection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Infection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Infección</s0>
<s5>07</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>137</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A87 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000A87 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0203512
   |texte=   Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus

Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri